Angelini Pharma

Angelini Pharma is the pharmaceutical division of Angelini Industries. The group began almost 100 years ago as a small pharmaceutical laboratory and over the years became a leading international group in the health area, present in both pharmaceuticals and Mass Market. Angelini Pharma is one of the leading pharmaceutical companies in healthcare, with particular focus and specialization in the fields of Mental Health and Epilepsy. It is also one of the leading pharmaceutical companies in the Consumer Health segment, with successful OTC brands worldwide. Angelini Pharma products are marketed in about 70 countries. The company operates directly in 20 countries, employing almost 3000 people, and markets its products in more than 70 countries through strategic alliances with leading international pharmaceutical groups. Angelini Pharma reported revenue of more than 1.2 billion euros in 2024, about half represented by exports. Angelini Pharma is an integrated pharmaceutical company with an extensive R&D operation that developed important molecules such as trazodone and benzydamine.

The group began almost 100 years ago as a small pharmaceutical laboratory and over the years became a leading international group in the health area, present in both pharmaceuticals and Mass Market. Angelini Pharma is the pharmaceutical division of Angelini Industries. Angelini Pharma is an integrated pharmaceutical company with an extensive R&D operation that developed important molecules such as trazodone and benzydamine. Currently, research, development and innovation programs focus on Brain Health, particularly Mental Health and Epilepsy, as well as Consumer Health.

• Unconfirmed

  Angelini Pharma acquires Arvelle Therapeutics[4]Angelini Pharma 收购 Arvelle Therapeuticspharmatimes.com

  Reported: 2021-01-05

  Angelini Pharma acquired Swiss biopharmaceutical company Arvelle Therapeutics for total consideration of up to $960 million. The acquisition gives Angelini exclusive licensing rights to commercialise cenobamate in the European Union and other countries in the European Economic Area, including Switzerland and the UK.

• 2021-01-04

  Angelini Pharma announced an agreement to acquire Arvelle Therapeutics[5]Angelini Pharma 宣布协议收购 Arvelle Therapeuticsprnewswire.co.uk

  Reported: 2021-01-04

  Angelini Pharma and Arvelle Therapeutics announced that they had concluded a definitive merger agreement under which Angelini Pharma would acquire Arvelle in an all-cash transaction valued at up to $960 million. Completion was subject to regulatory approval.

1. 1Angelini Pharmaangelinipharma.pt
2. 2Sobre Nósangelinipharma.pt
3. 3Angelini Pharma (Portugal)wikidata.org
4. 4Angelini Pharma 收购 Arvelle Therapeuticspharmatimes.com
5. 5Angelini Pharma 宣布协议收购 Arvelle Therapeuticsprnewswire.co.uk
6. 6Angelini Pharma acquires Arvelle Therapeutics to create a leading European innovator in Central Nervous System (CNS) and Mental Health Disorder treatmentsprnewswire.com